文献速递神经技术与安全MR

大鼠脑内钆潴留:重复给予钆基对比剂后不溶性含钆物质与完整钆复合物的定量评估

Gadolinium Retention in the Rat Brain: Assessment of the Amounts of Insoluble Gadolinium-containing Species and Intact Gadolinium Complexes after Repeated Administration of Gadolinium-based Contrast Agents.
PubMed 文献 · Radiology · 2017-09-04

研究在健康Wistar大鼠8周内给予总剂量13.2 mmol/kg的钆双胺或钆特醇,3天后取脑测定总钆浓度、完整钆复合物及不溶性含钆物质。钆特醇潴留远低于钆双胺,且检出的钆全部为完整可溶性对比剂;钆双胺则同时产生可溶性和不溶性含钆物质,以不溶性物质为主。

要点

  • 钆双胺脑内总钆浓度显著高于钆特醇,小脑最高(0.781 vs 0.061 μg/g)。
  • 钆特醇组检出的钆100%为完整可溶性对比剂。
  • 钆双胺组以小脑为例完整钆双胺仅占总钆18.2%±10.6,不溶性物质占主导。

核心结论

  • 钆特醇潴留远少于钆双胺,且检出的钆全部为完整可溶性对比剂;钆双胺则产生可溶性和不溶性含钆物质,以不溶性物质为主。

研究设计与样本

  • 动物实验:健康Wistar大鼠8周内给予总剂量13.2 mmol/kg的钆双胺或钆特醇,末次给药3天后处死取脑,匀浆后分别用电感耦合等离子体质谱测定总钆浓度、并测定完整钆复合物和不溶性含钆物质量。

关键影像表现/征象

  • 钆双胺与钆特醇平均总钆浓度分别为皮质0.317±0.060 vs 0.048±0.004 μg/g、皮质下脑0.418±0.078 vs 0.051±0.009 μg/g、小脑0.781±0.079 vs 0.061±0.012 μg/g。
  • 钆特醇组检出的钆100%为完整钆特醇。
  • 钆双胺组脑内潴留的钆以不溶性物质为主,小脑完整钆双胺占总钆的18.2%±10.6。
  • 钆质量平衡提示还存在其他可溶性含钆物质(约30%)。

诊断标准与关键数值

  • 体外形成的钆-聚唾液酸复合物在1.5 T、298 K下弛豫率为97.8 mM/sec。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To evaluate the speciation of gadolinium-containing species after multiple administrations of the gadolinium-based contrast agents (GBCAs) gadodiamide and gadoteridol and to quantify the amount of intact gadolinium complexes and insoluble gadolinium-containing species. Materials and Methods A total dose of 13.2 mmol per kilogram of body weight of each GBCA was administered in healthy Wistar rats over a period of 8 weeks. Three days after the final administration, rats were sacrificed, and the brains were excised and divided into three portions. Each portion of brain homogenate was divided into two parts, one for determination of the total gadolinium concentration with inductively coupled plasma mass spectrometry and one for determination of the amount of intact GBCA and gadolinium-containing insoluble species. Relaxometric measurements of gadodiamide and gadolinium trichloride in the presence of polysialic acid were also performed. Results The mean total gadolinium concentrations for gadodiamide and gadoteridol, respectively, were 0.317 μg/g ± 0.060 (standard deviation) and 0.048 μg/g ± 0.004 in the cortex, 0.418 μg/g ± 0.078 and 0.051 μg/g ± 0.009 in the subcortical brain, and 0.781 μg/g ± 0.079 and 0.061 μg/g ± 0.012 in the cerebellum. Gadoteridol comprised 100% of the gadolinium species found in rats treated with gadoteridol. In rats treated with gadodiamide, the largest part of gadolinium retained in brain tissue was insoluble species. In the cerebellum, the amount of intact gadodiamide accounts for 18.2% ± 10.6 of the total gadolinium found therein. The mass balance found for gadolinium implies the occurrence of other soluble gadolinium-containing species (approximately 30%). The relaxivity of the gadolinium polysialic acid species formed in vitro was 97.8 mM/sec at 1.5 T and 298 K. Conclusion Gadoteridol was far less retained, and the entire detected gadolinium was intact soluble GBCA, while gadodiamide yielded both soluble and insoluble gadolinium-containing species, with insoluble species dominating. © RSNA, 2017 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Gianolio E, Bardini P, Arena F, et al. Gadolinium Retention in the Rat Brain: Assessment of the Amounts of Insoluble Gadolinium-containing Species and Intact Gadolinium Complexes after Repeated Administration of Gadolinium-based Contrast Agents. Radiology. 2017. PMID: 28873047. doi:10.1148/radiol.2017162857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。